相似文献
1
Tumor growth in recurrent glioblastoma-RANO: when to plan the baseline scan?
Neuro Oncol. 2024 Aug 5;26(8):1536-1537. doi: 10.1093/neuonc/noae095.
2
Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial.
Neuro Oncol. 2017 Jun 1;19(6):853-861. doi: 10.1093/neuonc/now311.
3
Accuracy of High-Field Intraoperative MRI in the Detectability of Residual Tumor in Glioma Grade IV Resections.
Rofo. 2017 Jun;189(6):519-526. doi: 10.1055/s-0043-106189. Epub 2017 Jun 7.
4
Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma.
Neuroradiology. 2017 Feb;59(2):135-145. doi: 10.1007/s00234-016-1769-8. Epub 2017 Jan 9.
5
Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials.
Neurotherapeutics. 2017 Apr;14(2):307-320. doi: 10.1007/s13311-016-0507-6.
6
Combined iron oxide nanoparticle ferumoxytol and gadolinium contrast enhanced MRI define glioblastoma pseudoprogression.
Neuro Oncol. 2019 Mar 18;21(4):517-526. doi: 10.1093/neuonc/noy160.
7
Evaluation of the apparent diffusion coefficient in patients with recurrent glioblastoma under treatment with bevacizumab with radiographic pseudoresponse.
J Neuroradiol. 2019 Feb;46(1):36-43. doi: 10.1016/j.neurad.2018.04.002. Epub 2018 May 4.
8
Susceptibility and Tumor Size Changes During the Time Course of Standard Treatment in Recurrent Glioblastoma.
J Neuroimaging. 2019 Sep;29(5):645-649. doi: 10.1111/jon.12631. Epub 2019 May 21.
9
Measurable disease as baseline criterion for response assessment in glioblastoma: A comparison of PET -based (PET RANO 1.0) and MRI-based (RANO) assessments.
Neuro Oncol. 2025 Jan 12;27(1):77-88. doi: 10.1093/neuonc/noae208.
10
Recurrent pseudoprogression in isocitrate dehydrogenase 1 mutant glioblastoma.
J Clin Neurosci. 2018 Jul;53:255-258. doi: 10.1016/j.jocn.2018.04.056. Epub 2018 May 10.
引用本文的文献
1
RANO 2.0: critical updates and practical considerations for radiological assessment in neuro-oncology.
Jpn J Radiol. 2025 Jun 30. doi: 10.1007/s11604-025-01821-6.
2
Measurable disease as baseline criterion for response assessment in glioblastoma: A comparison of PET -based (PET RANO 1.0) and MRI-based (RANO) assessments.
Neuro Oncol. 2025 Jan 12;27(1):77-88. doi: 10.1093/neuonc/noae208.
本文引用的文献
1
RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults.
J Clin Oncol. 2023 Nov 20;41(33):5187-5199. doi: 10.1200/JCO.23.01059. Epub 2023 Sep 29.
2
Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival.
Neuro Oncol. 2023 Jun 2;25(6):1017-1028. doi: 10.1093/neuonc/noad002.
3
Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumors.
Neuro Oncol. 2022 Aug 1;24(8):1219-1229. doi: 10.1093/neuonc/noac086.
Zotero 插件